Senior Scientist / Scientist, Genome editing & next generation sequencing, Molecular Engineering

Fate Therapeutics is currently seeking a talented and motivated individual with expertise in molecular biology to join a multidisciplinary team dedicated to discovery and productization of novel off-the-shelf cell-based immunotherapies. Initially the candidate will perform molecular cloning, genome editing, and next generation sequencing (NGS) to support Fate's gene editing platform and preclinical pipelines. The position will evolve to include establishment of genomic analysis tools for NGS assays used in the manufacturing process and characterization of genetically engineered induced pluripotent stem cells (iPSCs). Candidate is highly desired to master molecular biology techniques and to independently design and deliver high quality results to meet Fate's aggressive timelines. This is a full-time position and is located at the company's corporate headquarters in San Diego.

Responsibilities:
• Design, perform, improve genome editing strategy and present experiments

independently
• Design and prepare independently for NGS assays
• Develop cutting edge NGS technology, identify creative solutions to problems and invent

new methodologies and workflows to improve sequencing technologies
• Establish and standardize methods and protocols for bioinformatical analysis of NGS data
• Develop and execute experimental plans in timelines to meet program and corporate

research objectives
• Communicate research and development findings in cross-disciplinary team meetings as

well as with external partners
• Record detailed experimental procedures in laboratory notebooks and controlled

documents

Qualifications
• Ph.D. degree in molecular biology or related fields with bioinformatics component.

Relevant experience in academic or industrial laboratories is highly desirable.
• Extensive experience in molecular cloning, gene editing technologies, including guide

RNA design and genomic cleavage assays.
• Expertise in sequencing and library prep methodologies is required.
• Prior experience in CRISPR-Cas genome editing and application of deep sequencing

strategies in genomic characterization and investigation is preferred.
• Experience in bioinformatics, NGS data analysis, and scientific programming is

preferable.
• Desire to understand the fundamental aspect of technologies, and the ability to identify

creative solutions to overcome current limitations.
• Good understanding of molecular biology techniques and troubleshooting thereof.

Proven ability to think innovatively toward solving problems effectively and efficiently
• Ability to design, implement, analyze and present experiments to demonstrate

feasibility of new methods and efficiently move products through pipeline.
• Comfortable in a fast-paced environment and able to adjust workload based upon changing priorities.
• Excellent communication and presentation skills.
• Post-doctoral or other experience of autonomous operation is a plus.

Working Conditions and Physical Requirements
• Will require working with blood and cell lines of human and animal origin
• Will require working with hazardous materials
• 100% on-site work at corporate headquarters in San Diego, CA
• Occasional evening and weekend work will be required

The preceding job description indicates the general nature and level of work performed by employees within this classification. Additional and incidental duties related to the primary duties may be required from time to time. For consideration send cover letter and curriculum vitae to: careers@fatetherapeutics.com and reference job 333PFT.

About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off- the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company's immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor- associated antigens with chimeric antigen receptors (CARs). The Company's immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.